Clinigen Group plc AGM Statement (9093O)
11 November 2016 - 6:00PM
UK Regulatory
TIDMCLIN
RNS Number : 9093O
Clinigen Group plc
11 November 2016
11 November 2016
AGM statement
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the
global pharmaceutical and services company, is holding its Annual
General Meeting ("AGM") at 10.00am today.
At the AGM, Peter Allen, Clinigen's Chairman will say:
"The year to 30 June 2016 marked the completion of our
transformation into the global market leader in the management and
supply of both unlicensed and clinical trial medicines.
"Alongside significant strategic progress, we delivered a strong
financial performance with good levels of organic growth combining
with acquisitions to increase adjusted EPS* by 25%. Trading for the
current financial year remains in line with the Board's
expectations.
"At the management level, as you know, Peter George will step
down as CEO after the AGM and Shaun Chilton will now take over. We
are pleased Peter will continue to work with the Group as a
Non-Executive Director.
"Our focus is now fixed on leveraging our global leadership
positions, and we will continue to drive organic growth supported
by acquisitions and the revitalisation of products."
*Adjusted basic earnings per share is excluding share based
payment costs, non-underlying costs, amortisation and associated
tax credit.
- Ends-
Clinigen Group plc Tel: +44 (0) 1283
495 010
Shaun Chilton, Group Chief
Executive Officer-designate
Martin Abell, Group Chief
Financial Officer
Matt Parrish, Head of Investor
Relations
Numis Securities Limited Tel: +44 (0) 20 7260
1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
Peel Hunt LLP Tel: +44 (0) 20 7418
8900
James Steel / Dr Christopher
Golden
Instinctif Partners (media Tel: +44 (0) 20 7457
relations) 2020
Melanie Toyne-Sewell / Jayne
Crook / Emma Barlow Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time.
The Group consists of five synergistic businesses focused in
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in
the management and supply of commercial medicines for clinical
trials.
The Group is also the trusted global leader in ethically
sourcing and supplying unlicensed medicines to hospital pharmacists
and physicians for patients with a high unmet need, through three
of its divisions:
Idis Managed Access runs early access programs for innovative
new medicines. Idis Global Access and Link Healthcare work directly
with healthcare professionals to enable compliant access to
unlicensed medicines on a global basis and niche essential licensed
and generic medicines across Australasia, Africa and Asia (AAA
region).
Clinigen Specialty Pharmaceuticals acquires global rights,
revitalises and markets its own portfolio of niche hospital
commercial products.
For more information, please visit www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMURUVRNSAAAAA
(END) Dow Jones Newswires
November 11, 2016 02:00 ET (07:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024